HIV molecular immunology database


Patient Detail

Patient Code 3043 (RV305# 3043)
Patient Sex
Risk Factor Other (OT)
Infection Country
Infection City
Infection Year
HLA Type
Patient Ethnicity Thai
Species human
Patient Note HIV-uninfected subject 3043 was part of the RV144 vaccine trial in Thailand and then the followup RV305 Group 1 vaccine boost (ALVAC-HIV plus AIDSVAX B/E gp120) 6-8 years later. Post-RV144, 106 mAbs were isolated of which 10 had long HCDR3s and mean VH nucleotide % mutation was 3.29. Post-RV305, 61 mAbs were isolated of which 16 had long HCDR3s and mean VH nucleotide % mutation was 7.27. 9 gp120-reactive B cell clonal lineages were common to both post-RV144 and -RV305 plasma, of which 2 (DH686 and DH576) had long HCDR3s. [Easterhoff2017 PMID 28235027]
CTL CD8+ Records
T-Helper CD4+ Records
Antibody Records DH576 (3837), DH576.1 (3838), DH576.2 (3839), DH577 (3840)
Sequence Database Patient ID Record
Questions or comments? Contact us at
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health